Inclusion Criteria:
* 1\. Subjects fully understand and voluntarily participate in this study and sign the informed consent form (ICF);
* 2\. 2-21 years old;
* 3\. Expected survival ≥ 3 months;
* 4\. Subjects with histologically confirmed diagnosis of relapsed and refractory lymphoma and solid tumors, which is one of the following subtypes:
1. Lymphoblastic lymphoma
2. Anaplastic large T cell lymphoma
3. Burkitt's lymphoma
4. Diffuse large B-cell lymphoma
5. Peripheral T, NK/T cell lymphoma
6. Soft tissue sarcoma
7. Neuroblastoma
8. Other subtypes of lymphoma or solid tumors that the investigators believe can be included
* 5\. Relapsed lymphoma is defined as the lymphoma that relapse after obtaining complete response (CR) after initial chemotherapy; Refractory lymphoma subjects meet one of the following conditions: 1) The tumor shrinks \<50% or disease progression after 4 cycles of standard chemotherapy,; 2) CR after standard chemotherapy, but relapse within half a year; 3) 2 or more relapses after CR; 4) relapse after hematopoietic stem cell transplantation;
* 6\. Lymphoma subjects must have at least one evaluable or measurable lesion per lugano2014 criteria: for lymph node lesions, the length should be \> 1.5cm; For non-lymph node lesions, the length should be \> 1.0cm;
* 7\. Solid tumors must have tumor lesions measurable by CT or MRI;
* 8\. ECOG Performance Status: 0-2;
* 9\. Bone marrow function: Absolute neutrophil count ≥1.5×109/L, Platelet count ≥75×109/L, Hemoglobin ≥ 80g/L (Absolute neutrophil can be relaxed to ≥ 1.0×109/L, Platelet count can be relaxed to ≥50×109/L, Hemoglobin can be relaxed to ≥75 g/L in subjects with poor bone-marrow reserve);
* 10\. Liver and kidney function: serum creatinine ≤ 1.5×ULN (upper limit of normal); AST and ALT ≤ 2.5×ULN (≤ 5×ULN for subjects with liver metastases); total bilirubin ≤ 1.5×ULN (≤ 3×ULN for subjects with liver metastases).
Exclusion Criteria:
* 1\. The subject had previously received any of the following anti-tumor treatments:
1. Subjects who have been treated with mitoxantrone or mitoxantrone liposomes;
2. Previously received doxorubicin or other anthracycline treatment, and the total cumulative dose of doxorubicin was more than 360 mg/m2 (1 mg doxorubicin equivalent to 2 mg epirubicin);
3. Subjects who received anti-tumor treatment (including chemotherapy, targeted therapy, glucocorticoid, traditional Chinese medicine with anti-tumor activity, etc.) or participated in other clinical trials and received trial drugs;
4. Subjects who received autologous hematopoietic stem cell transplantation within 100 days after the first medication or allogeneic hematopoietic stem cell transplantation.
* 2\. Hypersensitivity to any study drug or its components;
* 3\. Uncontrolled systemic diseases (such as active infection, uncontrolled hypertension, diabetes, etc.);
* 4\. Heart function and disease meet one of the following conditions:
1. Long QTc syndrome or QTc interval \> 480 ms;
2. Complete left bundle branch block, grade II or III atrioventricular block;
3. Serious and uncontrolled arrhythmias requiring drug treatment;
4. New York Heart Association grade ≥ III;
5. Cardiac ejection fraction (LVEF)\< 50%;
6. A history of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, a history of clinically serious pericardial disease, or ECG evidence of acute ischemia or active conduction system abnormalities within 6 months before recruitment.
* 5\. Hepatitis B and hepatitis C active infection (plus HBV DNA if one positive for hepatitis B surface antigen or core antibody and HBV DNA more than 1×103 copy/mL excluded; plus HCV RNA if hepatitis C antibody positive and HCV RNA more than 1×103 copy/mL exclude);
* 6\. Human immunodeficiency virus (HIV) infection (HIV antibody positive);
* 7\. Subjects with other malignant tumors past or present (except for non-melanoma skin basal cell carcinoma, breast/cervical carcinoma in control, and other malignant tumors that have been effectively controlled without treatment within the past five years);
* 8\. Subjects suffering from primary or secondary central nervous system (CNS) lymphoma or a history of CNS lymphoma at the time of recruitment;
* 9\. Pregnant and lactating women and childbearing age patients unwilling to take contraceptive measures;
* 10\. Unsuitable subjects for this study determined by the investigator.
